Please use this identifier to cite or link to this item:
Title: Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease
Author: Fernández-Nogales, Marta
Hernández, Félix
Miguez, Andrés
Alberch i Vié, Jordi
Ginés Padrós, Silvia
Pérez Navarro, Esther
Lucas, José J.
Keywords: Corea de Huntington
Proteïnes quinases
Inhibidors enzimàtics
Malalties neurodegeneratives
Cinètica enzimàtica
Huntington's chorea
Protein kinases
Enzyme inhibitors
Neurodegenerative Diseases
Enzyme kinetics
Issue Date: 1-Sep-2015
Publisher: Oxford University Press
Abstract: Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by brain atrophy particularly in striatum leading to personality changes, chorea and dementia. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase in the crossroad of many signaling pathways that is highly pleiotropic as it phosphorylates more than hundred substrates including structural, metabolic, and signaling proteins. Increased GSK-3 activity is believed to contribute to the pathogenesis of neurodegenerative diseases like Alzheimer's disease and GSK-3 inhibitors have been postulated as therapeutic agents for neurodegeneration. Regarding HD, GSK-3 inhibitors have shown beneficial effects in cell and invertebrate animal models but no evident efficacy in mouse models. Intriguingly, those studies were performed without interrogating GSK-3 level and activity in HD brain. Here we aim to explore the level and also the enzymatic activity of GSK-3 in the striatum and other less affected brain regions of HD patients and of the R6/1 mouse model to then elucidate the possible contribution of its alteration to HD pathogenesis by genetic manipulation in mice. We report a dramatic decrease in GSK-3 levels and activity in striatum and cortex of HD patients with similar results in the mouse model. Correction of the GSK-3 deficit in HD mice, by combining with transgenic mice with conditional GSK-3 expression, resulted in amelioration of their brain atrophy and behavioral motor and learning deficits. Thus, our results demonstrate that decreased brain GSK-3 contributes to HD neurological phenotype and open new therapeutic opportunities based on increasing GSK-3 activity or attenuating the harmful consequences of its decrease.
Note: Versió postprint del document publicat a:
It is part of: Human Molecular Genetics, 2015, vol. 24, num. 17, p. 5040-5052
Related resource:
ISSN: 0964-6906
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Biomedicina)
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
654617.pdf1.63 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.